These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
439 related articles for article (PubMed ID: 19546361)
41. Selective in vitro inhibition of Leishmania donovani by a semi-purified fraction of wild mushroom Grifola frondosa. Sultana SS; Ghosh J; Chakraborty S; Mukherjee D; Dey S; Mallick S; Dutta A; Paloi S; Khatua S; Dutta T; Bhattacharya S; Acharya K; Ghorai N; Pal C Exp Parasitol; 2018 Sep; 192():73-84. PubMed ID: 30040961 [TBL] [Abstract][Full Text] [Related]
42. Tadele M; Abay SM; Makonnen E; Hailu A Drug Des Devel Ther; 2020; 14():1307-1317. PubMed ID: 32280200 [TBL] [Abstract][Full Text] [Related]
43. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity. Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987 [TBL] [Abstract][Full Text] [Related]
44. Evaluation of antileishmanial drugs activities in an ex vivo model of leishmaniasis. Terreros MJS; de Luna LAV; Giorgio S Parasitol Int; 2019 Aug; 71():163-166. PubMed ID: 30991111 [TBL] [Abstract][Full Text] [Related]
45. In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. Seifert K; Escobar P; Croft SL J Antimicrob Chemother; 2010 Mar; 65(3):508-11. PubMed ID: 20089542 [TBL] [Abstract][Full Text] [Related]
46. Evaluation of in vitro antileishmanial efficacy of cyclosporin A and its non-immunosuppressive derivative, dihydrocyclosporin A. Zheng ZW; Li J; Chen H; He JL; Chen QW; Zhang JH; Zhou Q; Chen DL; Chen JP Parasit Vectors; 2020 Feb; 13(1):94. PubMed ID: 32085719 [TBL] [Abstract][Full Text] [Related]
47. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Sereno D; Cavaleyra M; Zemzoumi K; Maquaire S; Ouaissi A; Lemesre JL Antimicrob Agents Chemother; 1998 Dec; 42(12):3097-102. PubMed ID: 9835497 [TBL] [Abstract][Full Text] [Related]
48. In Vitro susceptibilities of wild and drug resistant Leishmania donovani amastigotes to piperolactam A loaded hydroxypropyl-β-cyclodextrin nanoparticles. Bhattacharya P; Mondal S; Basak S; Das P; Saha A; Bera T Acta Trop; 2016 Jun; 158():97-106. PubMed ID: 26940000 [TBL] [Abstract][Full Text] [Related]
49. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445 [TBL] [Abstract][Full Text] [Related]
50. Activity of a novel sulfonamide compound 2-nitro-N-(pyridin-2-ylmethyl)benzenesulfonamide against Leishmania donovani. Dikhit MR; Purkait B; Singh R; Sahoo BR; Kumar A; Kar RK; Ansari MY; Saini S; Abhishek K; Sahoo GC; Das S; Das P Drug Des Devel Ther; 2016; 10():1753-61. PubMed ID: 27307706 [TBL] [Abstract][Full Text] [Related]
51. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. Wyllie S; Cunningham ML; Fairlamb AH J Biol Chem; 2004 Sep; 279(38):39925-32. PubMed ID: 15252045 [TBL] [Abstract][Full Text] [Related]
52. In vitro antileishmanial activity of thioridazine on amphotericin B unresponsive/ sensitive Leishmania donovani promastigotes and intracellular amastigotes. Kumar V; Kumari S; Ranjan R; Kumar A; Alti D Exp Parasitol; 2024 Feb; 257():108688. PubMed ID: 38142765 [TBL] [Abstract][Full Text] [Related]
53. A mitochondrial HSP70 (HSPA9B) is linked to miltefosine resistance and stress response in Leishmania donovani. Vacchina P; Norris-Mullins B; Carlson ES; Morales MA Parasit Vectors; 2016 Dec; 9(1):621. PubMed ID: 27906059 [TBL] [Abstract][Full Text] [Related]
54. In vitro activity and mode of action of phenolic compounds on Leishmania donovani. Antwi CA; Amisigo CM; Adjimani JP; Gwira TM PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007206. PubMed ID: 30802252 [TBL] [Abstract][Full Text] [Related]
55. High-throughput Cos-Seq screen with intracellular Leishmania infantum for the discovery of novel drug-resistance mechanisms. Fernandez-Prada C; Sharma M; Plourde M; Bresson E; Roy G; Leprohon P; Ouellette M Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):165-173. PubMed ID: 29602064 [TBL] [Abstract][Full Text] [Related]
56. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Hadighi R; Boucher P; Khamesipour A; Meamar AR; Roy G; Ouellette M; Mohebali M Parasitol Res; 2007 Oct; 101(5):1319-22. PubMed ID: 17610079 [TBL] [Abstract][Full Text] [Related]
57. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Yardley V; Croft SL; De Doncker S; Dujardin JC; Koirala S; Rijal S; Miranda C; Llanos-Cuentas A; Chappuis F Am J Trop Med Hyg; 2005 Aug; 73(2):272-5. PubMed ID: 16103588 [TBL] [Abstract][Full Text] [Related]
58. N-(2-hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents. Nicoletti S; Seifert K; Gilbert IH Int J Antimicrob Agents; 2009 May; 33(5):441-8. PubMed ID: 19097763 [TBL] [Abstract][Full Text] [Related]
59. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Carter KC; Sundar S; Spickett C; Pereira OC; Mullen AB Antimicrob Agents Chemother; 2003 May; 47(5):1529-35. PubMed ID: 12709318 [TBL] [Abstract][Full Text] [Related]